Plasma neurofilament light chain levels in chemotherapy-induced peripheral neurotoxicity according to type of anticancer drug.
biomarkers
brentuximab vedotin
chemotherapy‐induced peripheral neurotoxicity
neurofilament light chain
oxaliplatin
paclitaxel
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
01 Jul 2024
01 Jul 2024
Historique:
revised:
19
04
2024
received:
20
02
2024
accepted:
12
05
2024
medline:
2
7
2024
pubmed:
2
7
2024
entrez:
2
7
2024
Statut:
aheadofprint
Résumé
A real-time biomarker in chemotherapy-induced peripheral neurotoxicity (CIPN) would be useful for clinical decision-making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN. This single-center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score-clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6-12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa Eighty-two patients, mostly women (59.8%), were included. One third of the patients who received TX (29.4%), BV (31%), or PT (36.8%) developed CR-CIPN, respectively, without differences among them (p = 0.854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0.001). A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
A real-time biomarker in chemotherapy-induced peripheral neurotoxicity (CIPN) would be useful for clinical decision-making during treatment. Neurofilament light chain (NfL) can be detected in blood in the case of neuroaxonal damage. The aim of the study was to compare the levels of plasma NfL (pNfL) according to the type of chemotherapeutic agent and the severity of CIPN.
METHODS
METHODS
This single-center prospective observational longitudinal study included patients treated with paclitaxel (TX; n = 34), brentuximab vedotin (BV; n = 29), or oxaliplatin (PT; n = 19). All patients were assessed using the Total Neuropathy Score-clinical version and Common Terminology Criteria for Adverse Events before, during, and up to 6-12 months after the end of treatment. Nerve conduction studies (NCS) were performed before and after chemotherapy discontinuation. Consecutive plasma samples were analyzed for NfL levels using a Simoa
RESULTS
RESULTS
Eighty-two patients, mostly women (59.8%), were included. One third of the patients who received TX (29.4%), BV (31%), or PT (36.8%) developed CR-CIPN, respectively, without differences among them (p = 0.854). Although pNfL significantly increased during treatment and decreased throughout the recovery period in all three groups, patients receiving TX showed significantly greater and earlier changes in pNfL levels compared to the other agents (p < 0.001).
CONCLUSIONS
CONCLUSIONS
A variable change in pNfL is observed depending on the type of agent and mechanism of neurotoxicity with comparable CIPN severity, strongly implying the need to identify different cutoff values for each agent.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16369Subventions
Organisme : Grupo Español en Investigación en Cáncer de Mama (GEICAM) Beca Balil-Pelegrí
Organisme : Instituto de Salud Carlos III
ID : PI20/00283
Organisme : Instituto de Salud Carlos III
ID : PI21/00181
Informations de copyright
© 2024 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Fridman V, Sillau S, Ritchie A, et al. Plasma neurofilament light chain concentrations are elevated in youth‐onset type 2 diabetes and associated with neuropathy. J Peripheral Nervous Sys. 2023;28:460‐470. doi:10.1111/jns.12575
Fundaun J, Kolski M, Molina‐Álvarez M, et al. Types and concentrations of blood‐based biomarkers in adults with peripheral neuropathies: a systematic review and meta‐analysis. JAMA Netw Open. 2022;5:e2248593. doi:10.1001/jamanetworkopen.2022.48593
Kmezic I, Samuelsson K, Finn A, et al. Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies. Eur J Neurol. 2022;29:2810‐2822. doi:10.1111/ene.15428
Karteri S, Bruna J, Argyriou AA, et al. Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients. J Peripheral Nervous Syst. 2022;27:166‐174. doi:10.1111/jns.12493
Velasco R, Argyriou AA, Marco C, et al. Serum neurofilament levels correlate with electrodiagnostic evidence of axonal loss in paclitaxel‐induced peripheral neurotoxicity. J Neurol. 2023;270:531‐537. doi:10.1007/s00415-022-11377-4
Park SB, Cetinkaya‐Fisgin A, Argyriou AA, Höke A, Cavaletti G, Alberti P. Axonal degeneration in chemotherapy‐induced peripheral neurotoxicity: clinical and experimental evidence. J Neurol Neurosurg Psychiatry. 2023;94:962‐972. doi:10.1136/jnnp-2021-328323
Cebulla N, Schirmer D, Runau E, et al. Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment. J Neurol. 2023;270:2997‐3007. doi:10.1007/s00415-023-11624-2
Mortensen C, Steffensen KD, Simonsen E, et al. Neurofilament light chain as a biomarker of axonal damage in sensory neurons and paclitaxel‐induced peripheral neuropathy in patients with ovarian cancer. Pain. 2022;164:1502‐1511. doi:10.1097/j.pain.0000000000002840
Kim S‐H, Choi MK, Park NY, et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin‐induced peripheral neuropathy. Sci Rep. 2020;10:7995. doi:10.1038/s41598-020-64511-5
Kim S‐H, Kim KH, Hyun J‐W, et al. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxel‐induced peripheral neuropathy in patients with gynecological cancers. Front Oncol. 2022;12:942960. doi:10.3389/fonc.2022.942960
Calls A, Torres‐Espin A, Tormo M, et al. A transient inflammatory response contributes to oxaliplatin neurotoxicity in mice. Ann Clin Transl Neurol. 2022;9:1985‐1998. doi:10.1002/acn3.51691
Velasco R, Alemany M, Villagrán M, Argyriou AA. Predictive biomarkers of oxaliplatin‐induced peripheral neurotoxicity. JPM. 2021;11:669. doi:10.3390/jpm11070669
Velasco R, Bruna J. Taxane‐induced peripheral neurotoxicity. Toxics. 2015;3:152‐169. doi:10.3390/toxics3020152
Velasco R, Domingo‐Domenech E, Sureda A. Brentuximab‐induced peripheral neurotoxicity: a multidisciplinary approach to manage an emerging challenge in Hodgkin lymphoma therapy. Cancers (Basel). 2021;13:6125. doi:10.3390/cancers13236125
Meregalli C, Fumagalli G, Alberti P, et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy‐induced peripheral neurotoxicity. Arch Toxicol. 2020;94:2517‐2522. doi:10.1007/s00204-020-02755-w
Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53:1660. doi:10.1212/WNL.53.8.1660
Argyriou AA, Bruna J, Kalofonou F, et al. Incidence and risk factors for developing chemotherapy‐induced neuropathic pain in 500 cancer patients: a file‐based observational study. J Peripher Nerv Syst. 2024;29:38‐46. doi:10.1111/jns.12616
Common Terminology Criteria for Adverse Events (CTCAE)|Protocol Development|CTEP. Accessed February 10, 2024. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Kimura J. Electrodiagnosis in Diseases of Nerve and Muscle: Principles and Practice. 4th ed. Oxford University Press; 2013.
Chen S, Andary M, Buschbacher R, et al. Electrodiagnostic reference values for upper and lower limb nerve conduction studies in adult populations. Muscle Nerve. 2016;54:371‐377. doi:10.1002/mus.25203
Velasco R, Bruna J, Briani C, et al. Early predictors of oxaliplatin‐induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry. 2014;85:392‐398. doi:10.1136/jnnp-2013-305334
England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of physical medicine and rehabilitation. Neurology. 2005;64:199‐207. doi:10.1212/01.WNL.0000149522.32823.EA
Simrén J, Andreasson U, Gobom J, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years. Brain Commun. 2022;4:fcac174. doi:10.1093/braincomms/fcac174
Chen J, Yang X, Zhang Y, et al. Reference values for plasma neurofilament light chain (NfL) in healthy Chinese. Clin Chem Lab Med. 2021;59:e153‐e156. doi:10.1515/cclm-2020-1030
Bornhorst JA, Figdore D, Campbell MR, et al. Plasma neurofilament light chain (NfL) reference interval determination in an age‐stratified cognitively unimpaired cohort. Clin Chim Acta. 2022;535:153‐156. doi:10.1016/j.cca.2022.08.017
Burgess BL, Cho E, Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy‐induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep. 2022;12:15593. doi:10.1038/s41598-022-18716-5
Huehnchen P, Schinke C, Bangemann N, et al. Neurofilament proteins as a potential biomarker in chemotherapy‐induced polyneuropathy. JCI Insight. 2022;7:e154395. doi:10.1172/jci.insight.154395
Briani C, Argyriou AA, Izquierdo C, et al. Long‐term course of oxaliplatin‐induced polyneuropathy: a prospective 2‐year follow‐up study. J Peripher Nerv Syst. 2014;19:299‐306. doi:10.1111/jns.12097
Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to neurologic disease. Ann Clin Transl Neurol. 2020;7:2508‐2523. doi:10.1002/acn3.51234
Chan ACY, Ong K, Ong JJY, Sharma VK, Wong HY, Vijayan J. Biomarkers in small fiber neuropathy. Explor Neuroprot Ther. 2022;2:264‐283. doi:10.37349/ent.2022.00033
Baka P, Steenken L, Escolano‐Lozano F, et al. Studying serum neurofilament light chain levels as a potential new biomarker for small fiber neuropathy. Eur J Neurol. 2024;31:e16192. doi:10.1111/ene.16192
Khalil M, Teunissen CE, Otto M, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577‐589. doi:10.1038/s41582-018-0058-z
Coppens S, Lehmann S, Hopley C, Hirtz C. Neurofilament‐light, a promising biomarker: analytical, metrological and clinical challenges. IJMS. 2023;24:11624. doi:10.3390/ijms241411624
Ladang A, Kovacs S, Lengelé L, et al. Neurofilament‐light chains (NF‐L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study. Aging Clin Exp Res. 2023;35:2029‐2037. doi:10.1007/s40520-023-02521-9
Velasco R, Petit J, Clapés V, Verdú E, Navarro X, Bruna J. Neurological monitoring reduces the incidence of bortezomib‐induced peripheral neuropathy in multiple myeloma patients. J Peripher Nerv Syst. 2010;15:17‐25. doi:10.1111/j.1529-8027.2010.00248.x
Argyriou AA, Park SB, Islam B, et al. Neurophysiological, nerve imaging and other techniques to assess chemotherapy‐induced peripheral neurotoxicity in the clinical and research settings. J Neurol Neurosurg. 2019;90:1361‐1369. doi:10.1136/jnnp-2019-320969
Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy‐induced peripheral neuropathy. Ann Oncol. 1998;9:739‐744. doi:10.1023/A:1008344507482